FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033363151> ?p ?o ?g. }

• W2033363151 endingPage "5872" @default.
• W2033363151 startingPage "5861" @default.
• W2033363151 abstract "The synthesis, molecular modeling, and pharmacological analysis of new multipotent simple, and readily available 2-aminopyridine-3,5-dicarbonitriles (3–20), and 2-chloropyridine-3,5-dicarbonitriles (21–28), prepared from 2-amino-6-chloropyridine-3,5-dicarbonitrile (1) and 2-amino-6-chloro-4-phenylpyridine-3,5-dicarbonitrile (2) is described. The biological evaluation showed that some of these molecules were modest inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), in the micromolar range. The 2-amino (3, 4), and 2-chloro derivatives 21–23, 25, 26 were AChE selective inhibitors, whereas 2-amino derivatives 5, 14 proved to be selective for BuChE. Only inhibitor 24 was equipotent for both cholinesterases. Kinetic studies on compound 23 showed that this compound is a mixed-type inhibitor of AChE showing a Ki of 6.33 μM. No clear SAR can be obtained form these data, but apparently, compounds bearing small groups such as the N,N′-dimethylamino or the pyrrolidino, regardless of the presence of a 2-amino, or 6-chloro substituent in the pyridine ring, preferentially inhibit AChE. Molecular modeling on inhibitors 4, 5, 22, and 23 has been carried out to give a better insight into the binding mode on the catalytic active site (CAS), and peripheral anionic site (PAS) of AChE. The most important differences in the observed binding relay on the modifications of the group at C2, as the amino group forms two hydrogen bonds that direct the binding mode, while in the case of compounds with a chlorine atom, this is not possible. The neuroprotective profile of these molecules has been investigated. In the LDH test, only compounds 26, 3, 22, and 24 showed neuroprotection with values in the range 37.8–31.6% in SH-SY5Y neuroblastoma cells stressed with a mixture of oligomycin-A/rotenone, but in the MTT test only compound 17 (32.9%) showed a similar profile. Consequently, these compounds can be considered as attractive multipotent therapeutic molecules on two key pharmacological receptors playing key roles in the progress of Alzheimer, that is, cholinergic dysfunction and oxidative stress, and neuronal vascular diseases." @default.
• W2033363151 created "2016-06-24" @default.
• W2033363151 creator A5017542552 @default.
• W2033363151 creator A5018104052 @default.
• W2033363151 creator A5020190176 @default.
• W2033363151 creator A5030157600 @default.
• W2033363151 creator A5044493452 @default.
• W2033363151 creator A5052444783 @default.
• W2033363151 creator A5054181608 @default.
• W2033363151 creator A5063076455 @default.
• W2033363151 creator A5070416857 @default.
• W2033363151 creator A5074411698 @default.
• W2033363151 creator A5080800757 @default.
• W2033363151 creator A5082905681 @default.
• W2033363151 creator A5089331022 @default.
• W2033363151 date "2010-08-01" @default.
• W2033363151 modified "2023-10-07" @default.
• W2033363151 title "Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles" @default.
• W2033363151 cites W1629179716 @default.
• W2033363151 cites W1965055466 @default.
• W2033363151 cites W1965300654 @default.
• W2033363151 cites W1971048984 @default.
• W2033363151 cites W1976042714 @default.
• W2033363151 cites W1976161355 @default.
• W2033363151 cites W1979521559 @default.
• W2033363151 cites W1981775239 @default.
• W2033363151 cites W1985026267 @default.
• W2033363151 cites W1985271495 @default.
• W2033363151 cites W1988037436 @default.
• W2033363151 cites W1991465998 @default.
• W2033363151 cites W2001226246 @default.
• W2033363151 cites W2001592736 @default.
• W2033363151 cites W2003618838 @default.
• W2033363151 cites W2004761754 @default.
• W2033363151 cites W2011000826 @default.
• W2033363151 cites W2015859691 @default.
• W2033363151 cites W2019397864 @default.
• W2033363151 cites W2025022665 @default.
• W2033363151 cites W2025204606 @default.
• W2033363151 cites W2025644108 @default.
• W2033363151 cites W2031362905 @default.
• W2033363151 cites W2031391963 @default.
• W2033363151 cites W2033054765 @default.
• W2033363151 cites W2034327787 @default.
• W2033363151 cites W2039069312 @default.
• W2033363151 cites W2039402692 @default.
• W2033363151 cites W2040018675 @default.
• W2033363151 cites W2047134066 @default.
• W2033363151 cites W2050025660 @default.
• W2033363151 cites W2059511731 @default.
• W2033363151 cites W2066510834 @default.
• W2033363151 cites W2066759595 @default.
• W2033363151 cites W2071109065 @default.
• W2033363151 cites W2072219894 @default.
• W2033363151 cites W2072243912 @default.
• W2033363151 cites W2081774366 @default.
• W2033363151 cites W2084107396 @default.
• W2033363151 cites W2085377099 @default.
• W2033363151 cites W2085736167 @default.
• W2033363151 cites W2089112315 @default.
• W2033363151 cites W2105259065 @default.
• W2033363151 cites W2126617728 @default.
• W2033363151 cites W2128540699 @default.
• W2033363151 cites W2143410390 @default.
• W2033363151 cites W2148999943 @default.
• W2033363151 cites W2155039139 @default.
• W2033363151 cites W2159373139 @default.
• W2033363151 cites W2165526004 @default.
• W2033363151 cites W2314547274 @default.
• W2033363151 cites W2950198475 @default.
• W2033363151 doi "https://doi.org/10.1016/j.bmc.2010.06.095" @default.
• W2033363151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20656495" @default.
• W2033363151 hasPublicationYear "2010" @default.
• W2033363151 type Work @default.
• W2033363151 sameAs 2033363151 @default.
• W2033363151 citedByCount "48" @default.
• W2033363151 countsByYear W20333631512012 @default.
• W2033363151 countsByYear W20333631512013 @default.
• W2033363151 countsByYear W20333631512014 @default.
• W2033363151 countsByYear W20333631512015 @default.
• W2033363151 countsByYear W20333631512016 @default.
• W2033363151 countsByYear W20333631512017 @default.
• W2033363151 countsByYear W20333631512018 @default.
• W2033363151 countsByYear W20333631512019 @default.
• W2033363151 countsByYear W20333631512020 @default.
• W2033363151 countsByYear W20333631512021 @default.
• W2033363151 countsByYear W20333631512022 @default.
• W2033363151 countsByYear W20333631512023 @default.
• W2033363151 crossrefType "journal-article" @default.
• W2033363151 hasAuthorship W2033363151A5017542552 @default.
• W2033363151 hasAuthorship W2033363151A5018104052 @default.
• W2033363151 hasAuthorship W2033363151A5020190176 @default.
• W2033363151 hasAuthorship W2033363151A5030157600 @default.
• W2033363151 hasAuthorship W2033363151A5044493452 @default.
• W2033363151 hasAuthorship W2033363151A5052444783 @default.
• W2033363151 hasAuthorship W2033363151A5054181608 @default.
• W2033363151 hasAuthorship W2033363151A5063076455 @default.
• W2033363151 hasAuthorship W2033363151A5070416857 @default.

• next